Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Stealth BioTherapeutics Inc / Equity Capital Markets

Stealth BioTherapeutics Inc (1628575D US)

Stealth Biotherapeutics, a U.S. based biotech company targeting rare disease caused by mitochondrial dysfunction, is planning to raise up to USD 200 million to list on the Hong Kong Stock Exchange.
In this insight, we will look at the following topics:
<ul>
<li>Mechanism of the peptide compound. </li>
<li>The company's pipeline indications.</li>
<li>The benefit of orphan drug development.</li>
<li>The addressable market for the company.</li>
<li>Key clinical trial results.</li>
<li>The company's investors and management.</li>
</ul>
We will discuss the company's valuation in our next insight.

Stealth Biotherapeutics, a U.S. based biotech company targeting rare disease caused by mitochondrial dysfunction, is planning to raise up to USD 200 million to list on the Hong Kong Stock Exchange.
In this insight, we will look at the following topics:

Mechanism of the peptide compound. 
The company's pipeline indications.
The benefit of orphan drug development.
The addressable market for the company.
Key clinical trial results.
The company's investors and management.

We will discuss the company's valuation in our next insight.

Stealth Biotherapeutics IPO: Cure the Symptoms but Not the Cause (Part 1)